Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AA4500 in Peyronie's Disease
NCT00755222Phase 2Completed
- Sponsor
- Endo International plc
- Start
- Aug 2008
- Primary completion
- Dec 2009
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Peyronie's disease comparing AA4500 with Placebo (2 arms). Primary endpoints: Change From Baseline in Penile Curvature at Week 36, Change From Baseline in Peyronie's Disease Questionnaire (PDQ) Peyronie's Disease Symptom Bother at Week 36 and 3 more. Started Aug 2008; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Peyronie's disease
Beyond the preview
Go deeper on NCT00755222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00755222.